Jul 15, 2021 / 02:00PM GMT
Tim Lugo - William Blair & Company, LLC - Analyst
I am Tim Lugo, Head of Biotech Research here at William Blair. And it's my pleasure to welcome Ian Mortimer, CEO of Xenon, as well as Simon Pimstone, Executive Chair of the Board at Xenon. And my Compliance Officer would definitely appreciate if I reminded everyone to look at williamblair.com for any relevant disclosures. And with that, Ian, maybe it is best to start off with just a brief overview of Xenon, your purpose, and focus of the Company.
Ian Mortimer - Xenon Pharmaceuticals Inc. - President & CEO
Perfect. Thanks, Tim, and good morning, everyone. And thanks to you and to William Blair for hosting us this morning. So I'll provide a bit of an overview of the Company and the pipeline, key programs, and then we'll make sure we have lots of time for Q&A. And I think we will dig deep in 1101, obviously a lot of focus on that program. We have an important clinical readout late September into mid-October. It's the guidance we are giving for topline data on our X-TOLE study, which is a Phase 2b clinical
Xenon Pharmaceuticals Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers